# Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

> **NCT06289062** · PHASE2 · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Cervical Cancer
- Neoadjuvant Chemoimmunotherapy
- Fertility Preservation

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Cisplatin
- **DRUG:** Nab paclitaxel
- **PROCEDURE:** biopsy

## Key facts

- **NCT ID:** NCT06289062
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-08
- **Primary completion:** 2025-12-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-11-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06289062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06289062, "Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT06289062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*